Weekly Investment Analysts’ Ratings Updates for Dermira (DERM)

A number of firms have modified their ratings and price targets on shares of Dermira (NASDAQ: DERM) recently:

  • 3/16/2018 – Dermira was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
  • 3/15/2018 – Dermira was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 3/8/2018 – Dermira was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
  • 3/6/2018 – Dermira was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 3/6/2018 – Dermira was downgraded by analysts at Guggenheim from a “buy” rating to a “neutral” rating.
  • 3/6/2018 – Dermira had its price target lowered by analysts at Needham & Company LLC from $43.00 to $19.00. They now have a “buy” rating on the stock.
  • 3/5/2018 – Dermira was downgraded by analysts at Mizuho from a “buy” rating to a “neutral” rating.
  • 3/5/2018 – Dermira was given a new $20.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 3/5/2018 – Dermira was given a new $25.00 price target on by analysts at Cowen Inc. They now have a “buy” rating on the stock.
  • 2/27/2018 – Dermira was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. “
  • 2/23/2018 – Dermira had its “buy” rating reaffirmed by analysts at Mizuho. They wrote, “We can attest that Dermira has been investing in pre-launch activities and had a strong presence at the AAD 2018 conference across all three of its key assets in acne, hyperhidrosis, and atopic dermatitis. We summarize 4Q:17 results in Exhibit 1 below. We reiterate our Buy rating in front of the binary acne read-out, which if positive, could drive significant upside to the stock. Data are expected in 1Q:18.””
  • 2/22/2018 – Dermira was given a new $45.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/5/2018 – Dermira was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 1/30/2018 – Dermira was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Dermira Inc (NASDAQ:DERM) traded down $0.41 during trading hours on Friday, hitting $8.33. The stock had a trading volume of 876,481 shares, compared to its average volume of 1,652,022. Dermira Inc has a fifty-two week low of $8.33 and a fifty-two week high of $36.21. The company has a debt-to-equity ratio of 1.87, a current ratio of 5.28 and a quick ratio of 5.28. The company has a market cap of $378.07, a PE ratio of -1.13 and a beta of 0.86.

How to Become a New Pot Stock Millionaire

Dermira (NASDAQ:DERM) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.25) by ($0.09). The business had revenue of $1.34 million for the quarter, compared to the consensus estimate of $1.10 million. Dermira had a negative net margin of 6,678.29% and a negative return on equity of 62.07%. equities analysts anticipate that Dermira Inc will post -4.66 earnings per share for the current year.

In other Dermira news, insider Eugene A. Bauer sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $28.55, for a total value of $85,650.00. Following the sale, the insider now owns 5,802 shares in the company, valued at approximately $165,647.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Christopher M. Griffith sold 18,458 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total value of $499,288.90. The disclosure for this sale can be found here. Insiders sold a total of 26,758 shares of company stock worth $728,459 in the last 90 days. Company insiders own 13.30% of the company’s stock.

Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.

Receive News & Ratings for Dermira Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

RTI Surgical  Lowered to Sell at BidaskClub
RTI Surgical Lowered to Sell at BidaskClub
Ovid Therapeutics  Earns Buy Rating from Analysts at Ladenburg Thalmann
Ovid Therapeutics Earns Buy Rating from Analysts at Ladenburg Thalmann
Vocera Communications  Stock Rating Upgraded by Zacks Investment Research
Vocera Communications Stock Rating Upgraded by Zacks Investment Research
BidaskClub Lowers Lakeland Financial  to Hold
BidaskClub Lowers Lakeland Financial to Hold
Microsoft  Given a $103.00 Price Target at Goldman Sachs
Microsoft Given a $103.00 Price Target at Goldman Sachs
Vipshop  Downgraded to “Hold” at Zacks Investment Research
Vipshop Downgraded to “Hold” at Zacks Investment Research


© 2006-2018 Ticker Report. Google+.